Skip to main content
SINPHAR logo

SINPHAR — Investor Relations & Filings

Ticker · 1734 ISIN · TW0001734002 TW Manufacturing
Open in API
Filings indexed 1,611 across all filing types
Latest filing 2024-03-06 Notice of Dividend Amou…
Country TW Taiwan
Listing TW 1734

About SINPHAR

www.sinphar.com

Sinphar Pharmaceutical Co., Ltd. is a vertically integrated pharmaceutical group specializing in the research, development, manufacturing, and distribution of therapeutic medicines, nutraceuticals, and medical cosmetics. Established in 1977, the company produces a diverse range of products, including Western and Chinese pharmaceuticals, specialized oncology drugs, and health supplements. Sinphar operates advanced R&D facilities and an ISO 17025-certified laboratory, leveraging high-precision technology for product innovation and quality assurance. Its business model encompasses proprietary brand management alongside professional OEM and ODM services for international markets. Key areas of expertise include the development of cancer treatments, functional health foods, and medical-grade skincare. Through its global marketing network and dedicated retail counters, Sinphar provides comprehensive healthcare solutions focused on life, health, and technology.

Recent filings

Filing Released Lang Actions
112年度股利金額(董事會決議)
Notice of Dividend Amount Classification · 95% confidence The document text primarily contains detailed information about dividend distribution, including cash dividends, stock dividends, and related shareholder meeting dates. It includes specific data on dividend amounts, dates of board resolutions, and shareholder meeting confirmations. This type of content is characteristic of a Notice of Dividend Amount, which announces dividend amounts, payment dates, and details for shareholders. The document is relatively short (1966 characters) and focused solely on dividend distribution details, with no comprehensive financial statements or broader annual or quarterly report content. Therefore, the appropriate classification is Notice of Dividend Amount (DIV).
2024-03-06 Chinese
公告本公司董事會決議召開113年股東常會相關事宜
AGM Information Classification · 95% confidence The document is a public announcement from a listed company (1734 杏輝) regarding the board of directors' resolution to convene the 113th Annual General Meeting (AGM). It details the date, location, and agenda items for the AGM, including reports, approvals, discussions, elections, and other matters. The document does not contain the actual AGM materials or presentations but rather the announcement of the meeting and its agenda. The document length is short (1054 characters), and it serves as a notice rather than the full AGM report or presentation. Therefore, it fits the category of AGM Information (AGM-R).
2024-03-06 Chinese
本公司董事會決議通過112年度合併財務報告案
Regulatory Filings Classification · 95% confidence The document is a brief announcement from the company's financial officer regarding the board's approval of the consolidated financial report for the fiscal year 112 (2023). It includes summarized financial data such as revenue, gross profit, operating profit, net profit, EPS, total assets, liabilities, and equity as of the fiscal year-end. The document length is only 908 characters, which is quite short and resembles a regulatory announcement rather than a full detailed report. There is no indication that this is the full annual report (10-K) or interim report (IR), but rather a notification of the board's resolution to approve the financial report. This fits best with a Regulatory Filing (RNS) as it is a formal disclosure of financial results without the full detailed report attached or included.
2024-03-06 Chinese
113年02月內部人持股異動(事後)
Director's Dealing Classification · 95% confidence The document contains detailed tabular data about shareholdings of company insiders, including directors, chairpersons, general managers, and their family members. It lists the number of shares held, changes in holdings, and other related information. This type of document is typical of a Director's Dealing report, which discloses personal share transactions by company directors and executives. There is no indication of financial statements, earnings data, or meeting materials. The document is not an announcement of voting results or a proxy statement, but a detailed insider shareholding disclosure. Therefore, the appropriate classification is Director's Dealing (DIRS).
2024-03-05 Chinese
113年02月董事會成員及持股
Director's Dealing Classification · 95% confidence The document is a detailed tabulation of shareholdings by insiders and related parties of the company 杏輝藥品工業股份有限公司. It lists positions such as Chairman, Vice Chairman, Directors, Independent Directors, General Manager, and other executives along with their shareholdings, pledged shares, and related party holdings. The document does not contain financial statements, earnings data, or management discussion. It is a disclosure of insider shareholdings and changes, which aligns with reporting of personal share transactions or holdings by company directors and executives. The document length is 3498 characters, which is relatively short but contains detailed insider shareholding data. This fits the definition of Director's Dealing (DIRS) filings, which report personal share transactions or holdings by company directors and executives. There is no indication that this is an announcement of a report or a certification letter, so it is not RNS or RPA. Therefore, the best classification is DIRS with high confidence.
2024-03-05 Chinese
113年1月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document is a financial disclosure from a listed company 杏輝, providing details on fund lending balances and endorsement guarantees for the current and previous months, including cumulative amounts and limits. The content is a regulatory disclosure of financial guarantees and related party transactions, typical of a regulatory announcement rather than a full financial report. The document length is short (624 characters), and it does not contain comprehensive financial statements or management discussion. It is not an announcement of a report publication but a direct regulatory disclosure. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory disclosures that do not fit other specific categories.
2024-02-15 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.